Pemafibrate reduced fibrinogen levels by a median of 58 mg/dL compared to control's 9 mg/dL increase over 12 weeks in patients with CAD and hypertriglyceridemia.
RCT (n=96)
Open-label
Computer algorithm 1:1 ratio stratified by age, fibrinogen level, antiplatelet monotherapy
Yes
Does pemafibrate reduce plasma fibrinogen levels in patients with coronary artery disease and hypertriglyceridemia on standard statin and antiplatelet therapy?
In patients with coronary artery disease and hypertriglyceridemia, pemafibrate significantly reduced fibrinogen and triglyceride levels but increased platelet count and in vitro thrombogenicity markers.
Effect estimate: Median change: -58 mg/dL in intervention vs +9 mg/dL in control
Absolute Event Rate: 241% vs 300%
p-value: p=<0.001
Pemafibrate significantly reduced fibrinogen levels in patients with CAD and hypertriglyceridemia, thus highlighting its primary benefit in lowering thrombotic risk.
Sato et al. (Thu,) conducted a rct in Patients with coronary artery disease and hypertriglyceridemia (fasting triglycerides ≥150 mg/dL) receiving antiplatelet monotherapy and statin therapy (n=96). Pemafibrate vs. Standard care without additional lipid-lowering therapy was evaluated on Change in plasma fibrinogen level from baseline to 12 weeks (Median change: -58 mg/dL in intervention vs +9 mg/dL in control, p=<0.001). Pemafibrate reduced fibrinogen levels by a median of 58 mg/dL compared to control's 9 mg/dL increase over 12 weeks in patients with CAD and hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: